A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associating 2 risk factors, total metabolic tumor volume (TM...

Descripción completa

Detalles Bibliográficos
Autores principales: Thieblemont, Catherine, Chartier, Loic, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F., Zaucha, Jan M., Vercellino, Laetitia, Gomes Silva, Maria, Patrocinio-Carvalho, Ines, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Oliver, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, N. George, Dunn, Joel, Cottereau, Anne-Ségolène, Schmitz, Christine, Kostakoglu, Lale, Paulson, Joseph N., Nielsen, Tina, Meignan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691911/
https://www.ncbi.nlm.nih.gov/pubmed/36044385
http://dx.doi.org/10.1182/bloodadvances.2021006923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691911/
https://www.ncbi.nlm.nih.gov/pubmed/36044385
http://dx.doi.org/10.1182/bloodadvances.2021006923

Ejemplares similares